Ranbaxy's Terapia gets approval for 20 new drugs

New Delhi, Mar 7 (UNI) Generic drug maker Ranbaxy Laboratories Ltd today said its Romanian unit, Terapia, has received market authorisation to sell 20 new products to be launched in the coming months.

''The list of Market Authorisations (MAs) granted by the National Agency of Medicine refers to products from different therapeutic areas mainly from the cardiovascular, antibiotics or CNS segments,'' said Mr Dragos Damian, CEO, Terapia Ranbaxy.

These are either new molecules on the market like Citaloran or unique and modern formulations or concentrationslike Lamotiran -- oral dispersible tablets, Pravator, Quinaran, Terbinaran or Glimeran, among others, he said.

These launches will help Terapia Ranbaxy, with a market share of 5.6 per cent, to bring value-added niche products at affordable prices to the Romanian pharmaceutical market.

With the commercial department structured in business units, Terapia Ranbaxy employs more than 1,200 people.

The company is undergoing an integration process including rebranding and training of the commercial force and registered a 50 per cent growth in 2006 in comparison to the previous year.

UNI